| Identification | Back Directory | [Name]
(S)-3-((S)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid | [CAS]
254750-02-2 | [Synonyms]
CS-1040
CS-2634
IDN 6556
EMricasan
abs816139
PF 03491390
Emricasan, (IDN-6556
Emricasan, PF 03491390
Emricasan(IDN6556,PF03491390)
IDN-6556;PF-03491390;PF03491390
(S)-3-((S)-2-(2-(2-tert-butylphenylaMino)-2-oxoacetaMido)propana
IDN 6556; PF 03491390; PF03491390; PF-03491390; IDN-6556;IDN6556;PF03491390
(S)-3-((S)-2-(2-((2-(tert-Butyl)phenyl)amino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tet
(S)-3-((S)-2-(2-((2-(tert-Butyl)phenyl)amino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetraf
(3S)-3-[(N-{[(2-tert-butylphenyl)amino](oxo)acetyl}-L-alanyl)amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
N-[2-(tert-butyl)phenyl]-2-oxoglycyl-N-[(1S)-1-(carboxymethyl)-2-oxo-3-(2,3,5,6-tetrafluorophenoxy)propyl]-L-alaninamide
(S)-3-((S)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
N-[2-(1,1-Dimethylethyl)phenyl]-2-oxoglycyl-N-[(1S)-1-(carboxymethyl)-2-oxo-3-(2,3,5,6-tetrafluorophenoxy)propyl]-L-alaninamide
L-Alaninamide, N-[2-(1,1-dimethylethyl)phenyl]-2-oxoglycyl-N-[(1S)-1-(carboxymethyl)-2-oxo-3-(2,3,5,6-tetrafluorophenoxy)propyl]-
(S)-3-((S)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid USP/EP/BP
EMricasan
(S)-3-((S)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid | [Molecular Formula]
C26H27F4NO7 | [MDL Number]
MFCD11840420 | [MOL File]
254750-02-2.mol | [Molecular Weight]
569.502 |
| Chemical Properties | Back Directory | [density ]
1.386 | [storage temp. ]
-20°C | [solubility ]
DMSO:42.0(Max Conc. mg/mL);73.75(Max Conc. mM)
Ethanol:100.0(Max Conc. mg/mL);175.59(Max Conc. mM) | [form ]
powder | [pka]
3.91±0.19(Predicted) | [color ]
white to beige | [CAS DataBase Reference]
254750-02-2 |
| Hazard Information | Back Directory | [Uses]
Emricasan is an irreversible pan-caspase inhibitor that hinders caspase-mediated apoptosis and inflammation.?In addition, Emricasan may reduce hepatic injury and liver fibrosis. | [Biological Activity]
Emricasan is an antiapoptotic pan-caspase inhibitor. It has been in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) with advanced fibrosis (scarring) and cirrhosis. Emricasan has also been shown to protect infected astrocytes from ZIKV-induced cell death.''Emricasanformerly known as IDN-6556in combination with birinapan is used to tre at acute myeloid leukemia (AML). This small molecule irreversible inhibitor is under clinical investigation to reduce hepatic injury and liver fibrosis. | [in vivo]
Emricasan (PF 03491390; IDN-6556) is orally active that is retained in the liver for a prolonged period of time. TUNEL-positive cells are considerably increased by five-fold in mice fed a HFD and are reduced under Emricasan treatment. In accordance with this observation caspase-3 and -8 are increased in HFD-fed mice by 1.5- and 1.3-fold respectively and are significantly decreased by Emricasan treatment[2].
When comparing efficacy by multiple routes of administration, Emricasan is administered i.p., p.o., i.m., or i.v. (0.03-3 mg/kg). Caspase 3-like activities, measured as DEVD-AMC cleavage, dose dependently decreased with a 92.5% reduction after the highest dose of Emricasan (3 mg/kg). Emricasan is initially tested in the α-Fas model of liver injury, marked hepatocellular apoptosis, and peak ALT activities within 6 h. Emricasan is administered i.p. immediately after administration of α-Fas, ALT activities, measured 6 h later, decreased in a dose-dependent manner with an ED50 value of 0.08 (0.06-0.12) mg/kg[3].
Emricasan is a highly selective pan-caspase inhibitor demonstrating irreversible inhibition and a significant first-pass effect. In both syngeneic mouse islets and human islets transplanted into immunodeficient mice, Emricasan (i.p., 20 mg/kg) given for 7 days post-transplant led to a significantly enhanced rate of diabetes reversal as compared to vehicle[4].
| [IC 50]
Caspase | [storage]
Store at -20°C |
|
|